SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ('SEED'), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED's ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted solid tumor indications.
SEED is advancing ST-01156 toward an Investigational New Drug (IND) application, with an expected IND filing in the first half of 2025. The Rare Pediatric Disease designation positions SEED to potentially receive an FDA priority review voucher upon approval of ST-01156.
SEED also announced that its largest shareholder, BeyondSpring Inc. (NASDAQ: BYSI) ('BeyondSpring'), has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED. Upon completion of the transactions, BeyondSpring is expected to retain approximately 14.4% of SEED's outstanding shares.
Pioneering Progress in Targeted Protein Degradation'SEED is rapidly transitioning into a clinical-stage company, with the planned IND filing in the next few months for ST-01156, our novel and potentially best-in-class RBM39 degrader. This marks a significant milestone in our four-year journey to bring innovative therapies to patients,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED and BeyondSpring. 'RBM39 is a validated target to address cancers with high unmet medical needs, as highlighted in a recent Nature Reviews Drug Discovery article. At SEED, we are committed to improving patient outcomes through pioneering science and rational drug development.'
FDA Recognition and Strategic Growth'The FDA's Rare Pediatric Disease and Orphan Drug designations for ST-01156 represent an important milestone, recognizing its potential to address significant unmet needs in rare oncology indications,' said Jackson Tai, Board Member of SEED. 'These designations may help expedite and reduce the cost of developing, approving, and commercializing this therapeutic agent.'
Tai added: 'The transactions announced today will diversify SEED's shareholder base. We believe this is a key step in ensuring that our capital structure and ownership distribution align with institutional investor expectations. SEED is now better positioned to pursue key initiatives, including advancing its clinical pipeline, extending its capital markets options, and maintaining its leadership in the field of targeted protein degradation.'
About SEED TherapeuticsSEED Therapeutics is an innovative biotech company focused on discovering and developing targeted protein degradation (TPD) therapeutics, with the mission to transform the treatment of diseases that currently have limited or no treatment options. Leveraging its cutting-edge RITE3™ platform, SEED is at the forefront of molecular glue-based TPD, addressing diseases in oncology and neurodegeneration. Through active collaborations with Eli Lilly and Company and Eisai Co., Ltd., and backed by a comprehensive intellectual property portfolio, SEED has built a robust pipeline of novel drug candidates now approaching clinical development. Visit www.seedtherapeutics.com to learn more.
About BeyondSpringBeyondSpring is a global clinical-stage biopharmaceutical company advancing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring is advancing its first-in-class lead asset, Plinabulin, into late-stage clinical development as a direct anti-cancer agent in non-small cell lung cancer (NSCLC) and other cancer indications. Plinabulin binds to a differentiated pocket in tubulin, distinct from other tubulin binders, and is a potent inducer of dendritic cell maturation, which activates both adaptive and innate immunity. In combination with docetaxel, Plinabulin has demonstrated significant overall survival benefits compared to docetaxel alone in second- and third-line NSCLC with EGFR wild type (Lancet Respir Med 2024). Additionally, Plinabulin has shown a significant reduction in severe neutropenia across multiple clinical studies. BeyondSpring's pipeline also includes three preclinical immuno-oncology assets. Visit www.beyondspringpharma.com for more information.
Investor Contact:IR@seedtherapeutics.com
Media Contact:PR@seedtherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
20 million eggs recalled from Walmart, Safeway other stores in WA, other states
A salmonella outbreak has caused the recall of 1.7 million dozen eggs and has sickened 79 people in seven states. Four people in Washington have been reported sick, and the U.S. Food and Drug Administration continues to track the outbreak. There have been no deaths. The recall was issued June 6 for 20 million eggs distributed to Walmart, Safeway, chains owned by Kroger and various other independent and chain supermarkets around the country. The Centers for Disease Control is recommending that people throw the eggs away. Hilmar, California's August Egg Co., a division of Gemperle Enterprises, produced the eggs and issued the recall last week. 'August Egg Company is not selling fresh shell eggs at this time,' the company-written, FDA-posted recall notice said. 'Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens.' Packaging for the recalled eggs will have plant code P-6562 or CA5330 with the Julian Dates between 32 to 126. The eggs that went to Walmart stores had sell-by dates from March 4 through June 19. Other retailers got eggs with 'sell by dates' from March 4 through June 4. The recall section of Walmart's website say the egg recall involves its stores in two dozen states, including Washington. The FDA's recall list includes California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. Here are specific brands to look for: ▪ Marketside (a Walmart store brand): Organic Large Cage Free Brown Eggs in cartons of 12 and 18; Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ First Street (a Smart & Final house brand): Cage Free Large Brown loose eggs. ▪ Clover: Organic Large Brown Eggs, one dozen. ▪ Nulaid: One dozen Medium Brown Cage Free, one dozen Jumbo Brown Cage Free. ▪ O Organics: Cage Free Large Brown, six eggs; and Large Brown, 12 and 18 eggs. This brand will be found at Safeway and other Albertson's-owned stores. ▪ Raley's (store brand): Large Cage Free Brown, 12 eggs: Organic Large Cage Free Brown, 12 and 18 eggs. ▪ Simple Truth: Cage Free Large Brown and Medium Brown 18 eggs. This brand will be found at Food 4 Less, Ralphs and other Kroger-owned chains. ▪ Sun Harvest: Organic Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ Sunnyside: Organic Large Cage Free Brown Eggs in cartons of 12 and 18; and Large Cage Free Brown Eggs in cartons of 12 and 18. An outbreak update from the Centers for Disease Control and Prevention says 79 people have been sickened in this outbreak with 21 hospitalizations. Most of those have been in California, with four in Washington. The remaining 10 break down as Nevada (four); Arizona (three); Nebraska and New Jersey (two each); and Kentucky (one). Salmonella outbreaks tend to be under-counted because most people recover without medical attention. The CDC estimates about 1.35 million people in the United States will get salmonella each year. Of that number, 26,400 will be hospitalized, usually driven to the hospital by bloody diarrhea, and 420 will die. Usually, salmonella means a few days of diarrhea, vomiting, fever and stomachaches. The Mayo Clinic notes that salmonella symptoms include: Nausea and/or vomiting Abdominal cramps Diarrhea and/or blood in the stool Fever Chills Headache If you have any of the recalled eggs listed above, return them to the store for a refund or throw them deep into the garbage. If you have any questions about the recalls, call August Farms at 800-710-2554, 9 a.m. to 5 p.m. daily, Pacific time.
Yahoo
25 minutes ago
- Yahoo
Dr Pepper recall upgraded over serious health risk
A recall on cases of Dr Pepper has been upgraded due to a serious health risk. On May 23, the United States Food and Drug Administration (FDA) and Dr Pepper issued a voluntary recall on 19,203 12-pack and 24-pack cases of 12-ounce cans of Dr Pepper Zero Sugar. Then, on Thursday, the FDA's recall was upgraded to Class II, which the organization describes as a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Although the cans, produced by Jacksonville, Florida-based Pepsi Beverages Company, were labeled 'zero sugar,' they were found to contain the full amount of sugar that is in a regular can, which is around 39 grams. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The soda was only distributed to retailers in Florida, Georgia, and South Carolina. The recall only applies to Dr Pepper Zero Sugar and not any other Dr Pepper products. Customers who have purchased the affected Dr Pepper cans are urged to return the product to where they were purchased in exchange for a full refund or to throw them away. A mislabel like this can lead to issues for anyone who needs to avoid sugar, or for diabetics who need to strictly monitor their sugar intake. If a person with diabetes eats too much sugar, it can lead to hyperglycemia, which is a condition where blood sugar levels become dangerously high, resulting in symptoms such as increased thirst and blurred vision. According to the Cleveland Clinic, if hyperglycemia is left untreated, it can develop into diabetes-related ketoacidosis (DKA), which can be fatal. The upgraded recall comes after Coca-Cola sent a letter to Costco members last week announcing that they were voluntarily recalling Topo Chico Mineral Water due to the possible presence of Pseudomonas aeruginosa, a bacteria that occurs naturally in water sources, including mineral water. According to the letter sent to customers, the health risks of consuming mineral water with Pseudomonas are 'very low' in healthy individuals and will only cause 'minor health consequences' in people with 'weakened immune systems.' 'The safety and quality of the products we offer our consumers is our top priority,' the letter read. The recall specifically applies to bottles that were sold at select Costco warehouses in Texas and Louisiana from May 20 to May 29, 2025. The water bottles were sold in 18-packs and have the lot number 13A2541 printed on both the case's packaging and the neck of the individual bottles. Customers who have purchased the affected water bottles are urged to return them to their local Costco in exchange for a full refund. Any questions regarding the recall can be directed to Coca-Cola using the phone number 1-800-GET-COKE.
Yahoo
40 minutes ago
- Yahoo
'RHONJ''s Dolores Catania Says She Gained 20 Lbs. After Mounjaro ‘Stopped Working': ‘I'm Having a Really Hard Time'
Dolores Catania revealed she gained 20 lbs. after her Mounjaro 'stopped working' The RHONJ star she's 'having a really hard time' dealing with the weight gain She admitted that there's a possibility her weight gain could be due to the slew of heart medications she's been takingDolores Catania is struggling with weight gain even while taking Mounjaro. On June 6, the Real Housewives of New Jersey star, 54, appeared on SiriusXM's Jeff Lewis Live and talked about taking Mounjaro, an FDA-approved prescription medication for people with type 2 diabetes. It's a brand name for tirzepatide, which is highly effective for weight loss by reducing appetite and improving how the body breaks down sugar and fat. Mounjaro is similar to Ozempic and Wegovy — brand names for semaglutide. They work in the brain to impact satiety and have been trending in and out of Hollywood. Catania — who previously shared that she lost 20 lbs. with the medication — revealed on the show that she's now gained the weight back. 'I'm having a really hard time right now. My Mounjaro stopped working, I gained 20 lbs.,' she shared. 'I've been looking for therapy for all my friends. I'm really having a bad time with this.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Lewis asked if she's able to switch to another medication like Ozempic and she immediately replied, 'I did it all.' Catania said she has since stopped taking the medication for about a month because she needed to undergo a cardiac ablation — a minimally invasive procedure where doctors freeze or burn the inside of the heart to restore a normal heart rhythm. The Bravo star assured that she's 'fine' now and was only in the hospital for the procedure. 'I'm on a bunch of medicine, like, 10 pills a day,' she said. 'It's just a formality now. I have to take it for the next 90 days, then I should be done.' 'Maybe that's why I gained weight,' she said of all the new medications. 'I'm hoping maybe that's why.' ! is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Catania previously spoke about her success on Mounjaro in 2023. "I'm down 20 pounds," she told The U.S. Sun, adding that her goal weight "is to be in the low 130s." The reality star admitted that she was previously 'gaining weight every month' and got up to 163 lbs. before trying the medication and seeing some results. 'It doesn't happen overnight. It doesn't come off easy," she said. Catania was originally prescribed Ozempic, taking the drug for two years before switching to Mounjaro in early 2023. 'I was medically prescribed for both because I am insulin resistant/pre-diabetic and have a thyroid issue,' she said at the time. Catania stressed that although she was still hoping to lose more weight on Mounjaro, taking these medications isn't a quick fix to weight loss, insisting that she focuses on exercising, healthy eating, and limiting her drinking — minus the wild nights spent with her RHONJ castmates. "I stopped taking [Ozempic] because it was expensive and everything. But being healthy and living a healthy lifestyle is cheap — it's free!" she told the outlet. "I work out regularly. There is no easy fix for weight loss and I have to watch what I eat." Read the original article on People
